Jianmin Pharmaceutical GroupLtd Toekomstige groei
Future criteriumcontroles 5/6
Jianmin Pharmaceutical GroupLtd is forecast to grow earnings and revenue by 26.8% and 14.4% per annum respectively. EPS is expected to grow by 26.7% per annum. Return on equity is forecast to be 21.2% in 3 years.
Belangrijke informatie
26.8%
Groei van de winst
26.7%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 19.3% |
Inkomstengroei | 14.4% |
Toekomstig rendement op eigen vermogen | 21.2% |
Dekking van analisten | Low |
Laatst bijgewerkt | 09 Sep 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity
Sep 25Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Aug 25The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%
Jul 12We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt
Jun 30We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease
May 21We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings
Apr 26Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 5,708 | 851 | N/A | 687 | 2 |
12/31/2025 | 5,116 | 707 | N/A | 359 | 2 |
12/31/2024 | 4,590 | 573 | N/A | 363 | 2 |
9/30/2024 | 3,977 | 428 | 91 | 206 | N/A |
6/30/2024 | 4,061 | 508 | 156 | 245 | N/A |
3/31/2024 | 4,170 | 521 | 214 | 284 | N/A |
12/31/2023 | 4,213 | 521 | 204 | 268 | N/A |
9/30/2023 | 3,948 | 508 | 221 | 287 | N/A |
6/30/2023 | 3,965 | 472 | 131 | 212 | N/A |
3/31/2023 | 3,736 | 419 | 196 | 270 | N/A |
12/31/2022 | 3,641 | 408 | 148 | 216 | N/A |
9/30/2022 | 3,503 | 363 | 96 | 152 | N/A |
6/30/2022 | 3,344 | 326 | 203 | 254 | N/A |
3/31/2022 | 3,376 | 324 | 37 | 88 | N/A |
12/31/2021 | 3,299 | 305 | 192 | 248 | N/A |
9/30/2021 | 3,456 | 279 | 197 | 253 | N/A |
6/30/2021 | 3,221 | 258 | 130 | 175 | N/A |
3/31/2021 | 2,857 | 199 | 127 | 175 | N/A |
1/1/2021 | 2,456 | 148 | 80 | 126 | N/A |
9/30/2020 | 2,013 | 144 | 94 | 149 | N/A |
6/30/2020 | 2,154 | 93 | 14 | 83 | N/A |
3/31/2020 | 2,164 | 83 | 11 | 81 | N/A |
1/1/2020 | 2,239 | 91 | 5 | 74 | N/A |
9/30/2019 | 2,402 | 82 | -32 | 35 | N/A |
6/30/2019 | 2,199 | 80 | -12 | 41 | N/A |
3/31/2019 | 2,183 | 79 | 27 | 73 | N/A |
1/1/2019 | 2,161 | 81 | 21 | 64 | N/A |
9/30/2018 | 2,188 | 91 | 51 | 92 | N/A |
6/30/2018 | 2,311 | 100 | N/A | 130 | N/A |
3/31/2018 | 2,625 | 102 | N/A | 93 | N/A |
12/31/2017 | 2,712 | 91 | N/A | 35 | N/A |
9/30/2017 | 2,748 | 81 | N/A | 72 | N/A |
6/30/2017 | 2,677 | 71 | N/A | 54 | N/A |
3/31/2017 | 2,315 | 59 | N/A | 41 | N/A |
12/31/2016 | 2,364 | 65 | N/A | 114 | N/A |
9/30/2016 | 2,495 | 69 | N/A | 87 | N/A |
6/30/2016 | 2,430 | 80 | N/A | 21 | N/A |
3/31/2016 | 2,449 | 83 | N/A | 2 | N/A |
12/31/2015 | 2,281 | 86 | N/A | 48 | N/A |
9/30/2015 | 1,953 | 86 | N/A | 49 | N/A |
6/30/2015 | 1,860 | 102 | N/A | 130 | N/A |
3/31/2015 | 1,748 | 114 | N/A | 107 | N/A |
12/31/2014 | 1,753 | 116 | N/A | 103 | N/A |
9/30/2014 | 1,685 | 118 | N/A | 56 | N/A |
6/30/2014 | 1,716 | 108 | N/A | 56 | N/A |
3/31/2014 | 1,867 | 98 | N/A | 89 | N/A |
12/31/2013 | 1,992 | 96 | N/A | 45 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 600976's forecast earnings growth (26.8% per year) is above the savings rate (2.9%).
Winst versus markt: 600976's earnings (26.8% per year) are forecast to grow faster than the CN market (25.8% per year).
Hoge groeiwinsten: 600976's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 600976's revenue (14.4% per year) is forecast to grow faster than the CN market (14% per year).
Hoge groei-inkomsten: 600976's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 600976's Return on Equity is forecast to be high in 3 years time (21.2%)